Welcome to our dedicated page for BlackRock ESG Capital Allocation Term SEC filings (Ticker: ECAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for BlackRock ESG Capital Allocation Term Trust (NYSE: ECAT) brings together the fund’s regulatory disclosures as a non-diversified, closed-end management investment company. As a registered investment company, ECAT files documents with the U.S. Securities and Exchange Commission that describe its structure, investment objectives, governance, and material corporate actions.
Regulatory materials referenced in public announcements include tender offer statements on Schedule TO, proxy statements for annual meetings, and related exhibits. Tender offer documents outline the terms under which ECAT has offered to repurchase a portion of its outstanding common shares, including the percentage of shares subject to the offer and the method for determining the purchase price as a percentage of net asset value on a specified date.
Proxy statements and associated filings provide details on proposals submitted to shareholders, such as the election of trustees and a shareholder proposal to terminate BlackRock Advisors, LLC as investment adviser. These filings also form the basis for recommendations issued by proxy advisory firms Institutional Shareholder Services, Glass Lewis, and Egan-Jones, which are discussed in Business Wire releases.
Litigation involving ECAT’s voting bylaws, brought by Saba Capital Management, L.P., is also connected to the fund’s regulatory framework under the Investment Company Act. Court rulings described in public news highlight questions about how ECAT’s voting standards interact with statutory requirements for shareholder elections and board composition.
On Stock Titan, ECAT’s SEC filings are supplemented with AI-powered summaries that explain the key points of lengthy documents in plain language. Real-time updates from the SEC’s EDGAR system allow users to see new filings as they appear, while AI-generated highlights help identify important items in tender offer statements, proxy materials, and other disclosures. This structure enables investors to review ECAT’s regulatory history, advisory arrangements, and governance-related filings more efficiently.
Saba Capital Management, L.P. reported an insider sale of
Saba Capital Management, L.P., a reporting person affiliated with director status, disclosed two open‑market sales of Common Stock of BlackRock ESG Capital Allocation Term Trust (ECAT). On
The Form 4 is signed by representatives with dates of signature on
Saba Capital Management, L.P. reported insider transactions in BlackRock ESG Capital Allocation Term Trust (ECAT). The filing shows two open‑market sales: 5,524 shares sold on
Saba Capital Management, L.P. reported two insider sales of BlackRock ESG Capital Allocation Term Trust (ECAT) common stock. On 09/30/2025 the reporting person sold 1,063 shares at $16.44, leaving 27,800,724 shares beneficially owned indirectly. On 10/01/2025 they sold 18,130 shares at $16.55, leaving 27,782,594 shares beneficially owned indirectly. The filer is identified as a Director and a 10% owner. The form is signed by Saba Capital Management, L.P., Zachary Gindes and Boaz Weinstein.
Saba Capital Management, L.P. reported an insider transaction in BlackRock ESG Capital Allocation Term Trust (ECAT) on a Form 4. The filing shows a sale of 1,113 shares of common stock on 09/25/2025 at a price of $16.24 per share. After the sale, the reporting person(s) beneficially owned 27,801,787 shares indirectly. The Form 4 is signed by Zachary Gindes and Boaz Weinstein on 09/29/2025.
Saba Capital Management, L.P. reported insider dispositions of BlackRock ESG Capital Allocation Term Trust (ECAT). The filing shows two sales: 17,785 shares sold on 09/23/2025 at $16.45 and 28,886 shares sold on 09/24/2025 at $16.39. After the transactions the reporting person beneficially owned 27,802,900 shares on an indirect basis, indicating continued substantial indirect ownership following the disposals.
Saba Capital Management, L.P. reported a sale of 5,776 shares of BlackRock ESG Capital Allocation Term Trust (ECAT) on 09/16/2025 at $16.51 per share. After the transaction the filer reports beneficial ownership of 27,849,571 shares held indirectly. The Form 4 is signed by representatives Zachary Gindes and Boaz Weinstein on 09/17/2025, and the filing indicates the reporting person is a director and a 10% owner.
Saba Capital Management, L.P. reported sales of common stock in BlackRock ESG Capital Allocation Term Trust (ECAT). The filing shows two transactions: on 09/11/2025 Saba sold 4,006 shares at $16.76, and on 09/12/2025 it sold 19,682 shares at $16.79, totaling 23,688 shares sold. After the transactions, Saba held 27,855,347 shares beneficially. The ownership is reported as indirect, and the reporting relationship checked indicates Director and 10% owner status. No derivative securities were reported. The form is signed by Zachary Gindes and Boaz Weinstein on 09/15/2025.
Saba Capital Management, L.P. and individual reporting person Boaz Weinstein filed a Form 4 disclosing sales of common stock of BlackRock ESG Capital Allocation Term Trust (ECAT). On 09/09/2025 they reported a sale of 76,416 shares at $16.69 and on 09/10/2025 a sale of 109,895 shares at $16.70. Following those sales the reporting entities beneficially owned 27,988,930 and 27,879,035 shares, respectively. The form is signed and dated 09/11/2025.
Saba Capital Management, L.P. and reporting person Boaz Weinstein disclosed a sale of common stock of BlackRock ESG Capital Allocation Term Trust (ECAT). On 09/08/2025 they sold 79,152 shares at $16.66 per share. After the transaction they report beneficial ownership of 28,065,346 shares, held indirectly. The filing lists the reporters as a director and a 10% owner.
FAQ
What is the current stock price of BlackRock ESG Capital Allocation Term (ECAT)?
What is the market cap of BlackRock ESG Capital Allocation Term (ECAT)?
